Immune microenvironment controls the outcome of PD‐1 blockade in cutaneous immune response
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and managementTherapeutic Advances in Medical Oncology, 2018
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Common clonal origin of central and resident memory T cells following skin immunizationNature Medicine, 2015
- T Cell Allorecognition via Molecular MimicryImmunity, 2009
- The PD-1–PD-L pathway in immunological toleranceTrends in Immunology, 2006
- Preferential contribution of B7‐H1 to programmed death‐1‐mediated regulation of hapten‐specific allergic inflammatory responsesEuropean Journal of Immunology, 2003
- The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) MiceJournal of Experimental Medicine, 2003
- Epitope spreadingCurrent Opinion in Immunology, 1996